choline has been researched along with Cirrhosis in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Decreased choline intake is significantly associated with increased fibrosis in postmenopausal women with NAFLD." | 9.16 | Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. ( Colvin, RM; Diehl, A; Guerrerio, AL; Lavine, JE; Mohan, P; Molleston, JP; Murray, KF; Scheimann, AO; Schwartz, AK; Schwimmer, JB; Torbenson, MS, 2012) |
| "This study demonstrated that RGS4 promoted cardiac fibrosis and attenuated the anti-cardiac fibrosis of choline." | 8.02 | The association between RGS4 and choline in cardiac fibrosis. ( Du, Z; Fan, Z; Guo, J; Hang, P; Li, W; Sun, Y; Yu, J; Zhao, X, 2021) |
| "A high-choline diet exacerbates cardiac dysfunction, myocardial fibrosis, and inflammation in HFpEF mice, and 3,3-dimethyl-1-butanol ameliorates the high-choline diet-induced cardiac remodeling." | 7.96 | High-Choline Diet Exacerbates Cardiac Dysfunction, Fibrosis, and Inflammation in a Mouse Model of Heart Failure With Preserved Ejection Fraction. ( Li, X; Li, Y; Shuai, W; Wang, D; Wen, J; Xiang, J, 2020) |
| "Heart failure severity is significantly enhanced in mice fed diets supplemented with either choline or the gut microbe-dependent metabolite TMAO." | 7.83 | Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure. ( Bhushan, S; Bradley, J; Hazen, SL; Lefer, DJ; Organ, CL; Otsuka, H; Polhemus, DJ; Tang, WH; Trivedi, R; Wang, Z; Wu, Y, 2016) |
| "1% methionine in HFCD diet suppressed body weight gain, which was lower than that with control diet." | 7.83 | Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice. ( Chiba, T; Itoh, T; Sato, Y; Suzuki, S; Umegaki, K, 2016) |
| "Quercetin (50 mg/kg) was given by oral route daily." | 5.38 | Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. ( González-Gallego, J; Marcolin, E; Marroni, N; San-Miguel, B; Tieppo, J; Tuñón, MJ; Vallejo, D, 2012) |
| "Decreased choline intake is significantly associated with increased fibrosis in postmenopausal women with NAFLD." | 5.16 | Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. ( Colvin, RM; Diehl, A; Guerrerio, AL; Lavine, JE; Mohan, P; Molleston, JP; Murray, KF; Scheimann, AO; Schwartz, AK; Schwimmer, JB; Torbenson, MS, 2012) |
| " Previously, we reported a dietary mouse NASH model with a choline-deficient, methionine-lowered, L-amino-acid-defined, high-fat diet containing shortening without trans fatty acids (CDAA-HF-T[-]), which rapidly induces fibrosis and proliferative lesions in the liver." | 4.31 | Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes. ( Abe, A; Miyajima, K; Nakae, D; Nakane, S; Suzuki-Kemuriyama, N; Yuki, M, 2023) |
| " High circulating levels of TMAO and its dietary precursor, choline, predict increased risk for development of CKD in apparently healthy subjects, and studies in mice fed TMAO or choline suggest that TMAO can contribute to kidney impairment and renal fibrosis." | 4.02 | Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice. ( Charugundla, S; Guo, F; Hazen, SL; Jia, X; Kaczor-Urbanowicz, KE; Lusis, AJ; Magyar, C; Miikeda, A; Nicholas, SB; Pellegrini, M; Shih, DM; Wang, Z; Zhang, W; Zhou, Z; Zuckerman, J, 2021) |
| "This study demonstrated that RGS4 promoted cardiac fibrosis and attenuated the anti-cardiac fibrosis of choline." | 4.02 | The association between RGS4 and choline in cardiac fibrosis. ( Du, Z; Fan, Z; Guo, J; Hang, P; Li, W; Sun, Y; Yu, J; Zhao, X, 2021) |
| "Gut microbial metabolism of dietary choline, a nutrient abundant in a Western diet, produces trimethylamine (TMA) and the atherothrombosis- and fibrosis-promoting metabolite TMA-N-oxide (TMAO)." | 3.96 | Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease. ( Buffa, JA; DiDonato, JA; Gupta, N; Hazen, SL; Ho, KJ; Li, L; Roberts, AB; Sangwan, N; Skye, SM; Tang, WHW; Varga, J, 2020) |
| "Background Patients at increased risk for coronary artery disease and adverse prognosis during heart failure exhibit increased levels of circulating trimethylamine N-oxide (TMAO), a metabolite formed in the metabolism of dietary phosphatidylcholine." | 3.96 | Nonlethal Inhibition of Gut Microbial Trimethylamine N-oxide Production Improves Cardiac Function and Remodeling in a Murine Model of Heart Failure. ( Goodchild, TT; Gupta, N; Hazen, SL; Lefer, DJ; Li, Z; Organ, CL; Polhemus, DJ; Sharp, TE; Tang, WHW, 2020) |
| "A high-choline diet exacerbates cardiac dysfunction, myocardial fibrosis, and inflammation in HFpEF mice, and 3,3-dimethyl-1-butanol ameliorates the high-choline diet-induced cardiac remodeling." | 3.96 | High-Choline Diet Exacerbates Cardiac Dysfunction, Fibrosis, and Inflammation in a Mouse Model of Heart Failure With Preserved Ejection Fraction. ( Li, X; Li, Y; Shuai, W; Wang, D; Wen, J; Xiang, J, 2020) |
| "Heart failure severity is significantly enhanced in mice fed diets supplemented with either choline or the gut microbe-dependent metabolite TMAO." | 3.83 | Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure. ( Bhushan, S; Bradley, J; Hazen, SL; Lefer, DJ; Organ, CL; Otsuka, H; Polhemus, DJ; Tang, WH; Trivedi, R; Wang, Z; Wu, Y, 2016) |
| " The aim of the present study was to elucidate the role of the TLR4‑dependent signaling pathway, and examine the effect of pioglitazone on hepatic fibrosis, through modulation of the TLR4 pathway in a mouse model of nutritional fibrotic steatohepatitis." | 3.83 | TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice. ( Du, J; Kong, L; Nan, Y; Niu, X; Wang, R; Zhang, Y; Zhao, S, 2016) |
| "1% methionine in HFCD diet suppressed body weight gain, which was lower than that with control diet." | 3.83 | Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice. ( Chiba, T; Itoh, T; Sato, Y; Suzuki, S; Umegaki, K, 2016) |
| "We found that concentrations of LPA and lysophosphatidylcholine accumulated in the effluent in the swollen pelvis of the ligated kidney of unilateral ureteral obstruction rats were much higher than those in the urinary bladder." | 3.77 | Presence of bioactive lysophosphatidic acid in renal effluent of rats with unilateral ureteral obstruction. ( Adachi, M; Morishige, J; Nikawadori, M; Tokumura, A; Tsutsumi, T, 2011) |
| "Expression of cyclooxygenase (COX)-2 protein during rat hepatocarcinogenesis associated with fatty change, fibrosis, cirrhosis and oxidative DNA damage, caused by a choline-deficient, L-amino acid-defined (CDAA) diet were investigated in F344 male rats, along with the chemopreventive efficacy of the specific COX-2 inhibitor, nimesulide (NIM)." | 3.71 | Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide. ( Denda, A; Kishida, H; Kitayama, W; Konishi, Y; Kusuoka, O; Murata, A; Nakae, D; Sasaki, Y; Takagi, H; Tsujiuchi, T; Tsutsumi, M, 2002) |
| "Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of liver damage directly related to diabetes, obesity, and metabolic syndrome." | 1.91 | (Pro)Renin Receptor Antagonism Attenuates High-Fat-Diet-Induced Hepatic Steatosis. ( Cooper, SG; Feng Earley, Y; Gayban, AJB; Kleemann, R; Regalado, E; Souza, LAC, 2023) |
| "While NKT-cell involvement in steatohepatitis is debated, discrepancies may stem from varied mouse strains used, predominantly C57BL6/J with Th1-dominant responses." | 1.91 | Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice. ( Andrés-Sánchez, N; Colell, A; Cuño-Gómiz, C; de Gregorio, E; Marí, M; Morales, A; Rider, P; Tutusaus, A, 2023) |
| "The pathogenesis of liver fibrosis requires activation of hepatic stellate cells (HSCs); once activated, HSCs lose intracellular fatty acids but the role of fatty acid oxidation and carnitine palmitoyltransferase 1A (CPT1A) in this process remains largely unexplored." | 1.72 | Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis. ( Alonso, C; Crespo, J; Cubero, FJ; da Silva Lima, N; Delgado, TC; Dieguez, C; Fernandez, U; Filliol, AA; Fondevila, MF; Gonzalez-Rellan, MJ; Heras, V; Herrero, L; Iglesias, C; Iruzubieta, P; López, M; Martinez-Chantar, ML; Mato, JM; Mayo, R; Millet, O; Nogueiras, R; Novoa, E; Parracho, T; Porteiro, B; Prevot, V; Schwabe, RF; Schwaninger, M; Senra, A; Serra, D; Varela-Rey, M; Woodhoo, A, 2022) |
| "Autophagy affects NAFLD by improving steatosis." | 1.72 | Ubiquitin-specific peptidase 10 ameliorates hepatic steatosis in nonalcoholic steatohepatitis model by restoring autophagic activity. ( Xin, SL; Yu, YY, 2022) |
| "Nonalcoholic steatohepatitis has emerged as a major cause of liver diseases with no effective therapies." | 1.56 | The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates. ( Chen, J; Cui, A; Gao, J; Han, J; Ji, S; Li, J; Li, Y; Liu, Z; Ma, F; Ma, X; Tai, P; Wang, G; Wang, T; Xue, Y, 2020) |
| "Choline treatment may represent a new therapeutic strategy for optimizing myocardial metabolism in the context of hypertrophy and heart failure." | 1.51 | Choline ameliorates cardiac hypertrophy by regulating metabolic remodelling and UPRmt through SIRT3-AMPK pathway. ( Cui, YL; Lu, Y; Wu, Q; Xu, M; Xue, RQ; Yong, SY; Yu, XJ; Zang, WJ; Zhao, M; Zuo, XT, 2019) |
| "Although therapeutic intervention for nonalcoholic steatohepatitis (NASH) at an early stage is important owing to the progressive nature of the disease, diagnosis using noninvasive methods remains difficult." | 1.40 | Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. ( Fujita, K; Imajo, K; Kessoku, T; Kirikoshi, H; Mawatari, H; Nakajima, A; Nozaki, Y; Ogawa, Y; Saito, S; Sekino, Y; Shinohara, Y; Taguri, M; Takahashi, J; Tomeno, W; Toshima, G; Wada, K; Yoneda, M, 2014) |
| "Quercetin (50 mg/kg) was given by oral route daily." | 1.38 | Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. ( González-Gallego, J; Marcolin, E; Marroni, N; San-Miguel, B; Tieppo, J; Tuñón, MJ; Vallejo, D, 2012) |
| "Thus, effective treatment of fibrosis in inflammatory bowel disease may require early and complete blockade of NF-kappaB with particular attention to specific proinflammatory and profibrogenic genes that remain active at low levels of NF-kappaB." | 1.34 | Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappaB inhibition in a mouse model of chronic colitis. ( Chakravarti, S; Wu, F, 2007) |
| "Nonalcoholic steatohepatitis (NASH) may cause fibrosis, cirrhosis, and hepatocellular carcinoma (HCC); however, the exact mechanism of disease progression is not fully understood." | 1.33 | Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. ( Akahane, T; Asada, K; Fukui, H; Ikenaka, Y; Kaji, K; Kitade, M; Kojima, H; Namisaki, T; Noguchi, R; Tsujimoto, T; Uemura, M; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (8.82) | 29.6817 |
| 2010's | 12 (35.29) | 24.3611 |
| 2020's | 18 (52.94) | 2.80 |
| Authors | Studies |
|---|---|
| Fondevila, MF | 1 |
| Fernandez, U | 1 |
| Heras, V | 1 |
| Parracho, T | 1 |
| Gonzalez-Rellan, MJ | 1 |
| Novoa, E | 1 |
| Porteiro, B | 1 |
| Alonso, C | 1 |
| Mayo, R | 1 |
| da Silva Lima, N | 1 |
| Iglesias, C | 1 |
| Filliol, AA | 1 |
| Senra, A | 1 |
| Delgado, TC | 1 |
| Woodhoo, A | 1 |
| Herrero, L | 1 |
| Serra, D | 1 |
| Prevot, V | 1 |
| Schwaninger, M | 1 |
| López, M | 1 |
| Dieguez, C | 1 |
| Millet, O | 1 |
| Mato, JM | 1 |
| Cubero, FJ | 1 |
| Varela-Rey, M | 1 |
| Iruzubieta, P | 1 |
| Crespo, J | 1 |
| Martinez-Chantar, ML | 1 |
| Schwabe, RF | 1 |
| Nogueiras, R | 1 |
| Xin, SL | 1 |
| Yu, YY | 1 |
| Zhao, M | 2 |
| Ma, L | 1 |
| Honda, T | 1 |
| Kato, A | 1 |
| Ohshiro, T | 1 |
| Yokoyama, S | 1 |
| Yamamoto, K | 1 |
| Ito, T | 1 |
| Imai, N | 1 |
| Ishizu, Y | 1 |
| Nakamura, M | 1 |
| Kawashima, H | 1 |
| Tsuji, NM | 1 |
| Ishigami, M | 1 |
| Fujishiro, M | 1 |
| Kong, W | 1 |
| Tang, Y | 1 |
| Liu, L | 2 |
| Zhang, G | 1 |
| Liu, Y | 1 |
| Liu, J | 1 |
| Zan, K | 1 |
| Lei, W | 1 |
| Li, Y | 3 |
| Wang, Y | 1 |
| Zuo, T | 1 |
| Jin, H | 1 |
| Ma, S | 1 |
| Aljobaily, N | 1 |
| Krutsinger, K | 1 |
| Viereckl, MJ | 1 |
| Joly, R | 1 |
| Menlove, B | 1 |
| Cone, B | 1 |
| Suppes, A | 1 |
| Han, Y | 1 |
| Gayban, AJB | 1 |
| Souza, LAC | 1 |
| Cooper, SG | 1 |
| Regalado, E | 1 |
| Kleemann, R | 1 |
| Feng Earley, Y | 1 |
| Zhen, Q | 1 |
| Liang, Q | 1 |
| Wang, H | 1 |
| Zheng, Y | 1 |
| Lu, Z | 1 |
| Bian, C | 1 |
| Zhao, X | 2 |
| Guo, X | 1 |
| Suzuki-Kemuriyama, N | 1 |
| Abe, A | 1 |
| Nakane, S | 1 |
| Yuki, M | 1 |
| Miyajima, K | 1 |
| Nakae, D | 2 |
| Cuño-Gómiz, C | 1 |
| de Gregorio, E | 1 |
| Tutusaus, A | 1 |
| Rider, P | 1 |
| Andrés-Sánchez, N | 1 |
| Colell, A | 1 |
| Morales, A | 1 |
| Marí, M | 1 |
| Gupta, N | 2 |
| Buffa, JA | 1 |
| Roberts, AB | 1 |
| Sangwan, N | 1 |
| Skye, SM | 1 |
| Li, L | 1 |
| Ho, KJ | 1 |
| Varga, J | 1 |
| DiDonato, JA | 1 |
| Tang, WHW | 2 |
| Hazen, SL | 4 |
| Cui, A | 1 |
| Li, J | 1 |
| Ji, S | 1 |
| Ma, F | 1 |
| Wang, G | 1 |
| Xue, Y | 1 |
| Liu, Z | 1 |
| Gao, J | 1 |
| Han, J | 1 |
| Tai, P | 1 |
| Wang, T | 1 |
| Chen, J | 1 |
| Ma, X | 1 |
| Organ, CL | 2 |
| Li, Z | 1 |
| Sharp, TE | 1 |
| Polhemus, DJ | 2 |
| Goodchild, TT | 1 |
| Lefer, DJ | 2 |
| Shuai, W | 1 |
| Wen, J | 1 |
| Li, X | 1 |
| Wang, D | 1 |
| Xiang, J | 1 |
| Esposito, G | 1 |
| Schiattarella, GG | 1 |
| Leclère, PS | 1 |
| Rousseau, D | 1 |
| Patouraux, S | 1 |
| Guérin, S | 1 |
| Bonnafous, S | 1 |
| Gréchez-Cassiau, A | 1 |
| Ruberto, AA | 1 |
| Luci, C | 1 |
| Subramaniam, M | 1 |
| Tran, A | 1 |
| Delaunay, F | 1 |
| Gual, P | 1 |
| Teboul, M | 1 |
| Zhang, W | 1 |
| Miikeda, A | 1 |
| Zuckerman, J | 1 |
| Jia, X | 1 |
| Charugundla, S | 1 |
| Zhou, Z | 1 |
| Kaczor-Urbanowicz, KE | 1 |
| Magyar, C | 1 |
| Guo, F | 1 |
| Wang, Z | 2 |
| Pellegrini, M | 1 |
| Nicholas, SB | 1 |
| Lusis, AJ | 1 |
| Shih, DM | 1 |
| Guo, J | 1 |
| Hang, P | 1 |
| Yu, J | 1 |
| Li, W | 1 |
| Sun, Y | 1 |
| Fan, Z | 1 |
| Du, Z | 1 |
| Xu, M | 1 |
| Xue, RQ | 1 |
| Lu, Y | 1 |
| Yong, SY | 1 |
| Wu, Q | 1 |
| Cui, YL | 1 |
| Zuo, XT | 1 |
| Yu, XJ | 1 |
| Zang, WJ | 1 |
| Xiao, J | 1 |
| Wang, F | 1 |
| Liong, EC | 1 |
| So, KF | 1 |
| Tipoe, GL | 1 |
| Trump, T | 1 |
| Luchey, AM | 1 |
| Hogg, J | 1 |
| Mattes, MD | 1 |
| Imajo, K | 1 |
| Yoneda, M | 1 |
| Fujita, K | 1 |
| Kessoku, T | 1 |
| Tomeno, W | 1 |
| Ogawa, Y | 1 |
| Shinohara, Y | 1 |
| Sekino, Y | 1 |
| Mawatari, H | 1 |
| Nozaki, Y | 1 |
| Kirikoshi, H | 1 |
| Taguri, M | 1 |
| Toshima, G | 1 |
| Takahashi, J | 1 |
| Saito, S | 1 |
| Wada, K | 1 |
| Nakajima, A | 1 |
| Shimozono, R | 1 |
| Asaoka, Y | 1 |
| Yoshizawa, Y | 1 |
| Aoki, T | 1 |
| Noda, H | 1 |
| Yamada, M | 1 |
| Kaino, M | 1 |
| Mochizuki, H | 1 |
| Chen, R | 1 |
| Wang, Q | 1 |
| Song, S | 1 |
| Liu, F | 1 |
| He, B | 1 |
| Gao, X | 1 |
| Otsuka, H | 1 |
| Bhushan, S | 1 |
| Bradley, J | 1 |
| Trivedi, R | 1 |
| Tang, WH | 1 |
| Wu, Y | 1 |
| Du, J | 1 |
| Niu, X | 1 |
| Wang, R | 1 |
| Zhao, S | 1 |
| Kong, L | 1 |
| Zhang, Y | 1 |
| Nan, Y | 1 |
| Chiba, T | 1 |
| Suzuki, S | 1 |
| Sato, Y | 1 |
| Itoh, T | 1 |
| Umegaki, K | 1 |
| Tsutsumi, T | 1 |
| Adachi, M | 1 |
| Nikawadori, M | 1 |
| Morishige, J | 1 |
| Tokumura, A | 1 |
| Guerrerio, AL | 1 |
| Colvin, RM | 1 |
| Schwartz, AK | 1 |
| Molleston, JP | 1 |
| Murray, KF | 1 |
| Diehl, A | 1 |
| Mohan, P | 1 |
| Schwimmer, JB | 1 |
| Lavine, JE | 1 |
| Torbenson, MS | 1 |
| Scheimann, AO | 1 |
| Marcolin, E | 1 |
| San-Miguel, B | 1 |
| Vallejo, D | 1 |
| Tieppo, J | 1 |
| Marroni, N | 1 |
| González-Gallego, J | 1 |
| Tuñón, MJ | 1 |
| OHTA, Y | 1 |
| ZAKI, FG | 1 |
| HOFFBAUER, FW | 1 |
| Kitade, M | 1 |
| Yoshiji, H | 1 |
| Kojima, H | 1 |
| Ikenaka, Y | 1 |
| Noguchi, R | 1 |
| Kaji, K | 1 |
| Yoshii, J | 1 |
| Yanase, K | 1 |
| Namisaki, T | 1 |
| Asada, K | 1 |
| Yamazaki, M | 1 |
| Tsujimoto, T | 1 |
| Akahane, T | 1 |
| Uemura, M | 1 |
| Fukui, H | 1 |
| Wu, F | 1 |
| Chakravarti, S | 1 |
| Denda, A | 1 |
| Kitayama, W | 1 |
| Murata, A | 1 |
| Kishida, H | 1 |
| Sasaki, Y | 1 |
| Kusuoka, O | 1 |
| Tsujiuchi, T | 1 |
| Tsutsumi, M | 1 |
| Takagi, H | 1 |
| Konishi, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)[NCT00063635] | Phase 3 | 173 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Clinical Research Network in Nonalcoholic Steatohepatitis: Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)[NCT00063622] | Phase 3 | 247 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | kg/m-squared (Mean) |
|---|---|
| Metformin | 1.3 |
| Vitamin E | 2.1 |
| Placebo | 1.9 |
Histological activity was assessed using the NAFLD activity score on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2). (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Metformin | -1.1 |
| Vitamin E | -1.8 |
| Placebo | -0.7 |
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Metformin | 4.0 |
| Vitamin E | 6.0 |
| Placebo | 5.6 |
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Metformin | 5.4 |
| Vitamin E | 7.6 |
| Placebo | 5.4 |
(NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | IU/L (Mean) |
|---|---|
| Metformin | -21.5 |
| Vitamin E | -22.8 |
| Placebo | -20.4 |
Change in alpha-Tocopherol (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | mg/L (Mean) |
|---|---|
| Metformin | -0.5 |
| Vitamin E | 9.4 |
| Placebo | -0.9 |
Ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe ballooning. This secondary outcome measure is the number of participants that experienced a decrease in ballooning score at 96 weeks compared to baseline, which indicates improvement in ballooning. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 22 |
| Vitamin E | 22 |
| Placebo | 10 |
Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score at 96 weeks compared to baseline, which indicates improvement in fibrosis. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 22 |
| Vitamin E | 18 |
| Placebo | 19 |
Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score at 96 weeks compared to baseline, which indicates improvement in lobular inflammation. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 23 |
| Vitamin E | 22 |
| Placebo | 20 |
Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score at 96 weeks compared to baseline, which indicates improvement in steatosis. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 26 |
| Vitamin E | 27 |
| Placebo | 19 |
The primary outcome was sustained reduction in ALT level, defined as 50% or less of the baseline level or 40 IU/L or less at each visit from 48 to 96 weeks of treatment. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 9 |
| Vitamin E | 15 |
| Placebo | 10 |
Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score, which indicates improvement in fibrosis. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 31 |
| Vitamin E | 33 |
| Placebo | 22 |
Hepatocellular ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe hepatocellular ballooning. This secondary outcome measure is the number of participants that experienced a decrease in hepatocellular ballooning score, which indicates improvement in hepatocellular ballooning. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 31 |
| Vitamin E | 40 |
| Placebo | 21 |
Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score, which indicates improvement in lobular inflammation. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 41 |
| Vitamin E | 43 |
| Placebo | 25 |
Total nonalcoholic fatty liver disease (NAFLD) activity was assessed on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (assessed on a scale of 0 to 3), lobular inflammation (assessed on a scale of 0 to 3), and hepatocellular ballooning (assessed on a scale of 0 to 2). The primary outcome was an improvement in histological findings from baseline to 96 weeks, which required an improvement by 1 or more points in the hepatocellular ballooning score; no increase in the fibrosis score; and either a decrease in the activity score for nonalcoholic fatty liver disease to a score of 3 or less or a decrease in the activity score of at least 2 points, with at least a 1-point decrease in either the lobular inflammation or steatosis score. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 27 |
| Vitamin E | 36 |
| Placebo | 16 |
Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score, which indicates improvement in steatosis. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 48 |
| Vitamin E | 43 |
| Placebo | 22 |
The criteria for nonalcoholic steatohepatitis was definite or possible steatohepatitis (assessed by a pathologist) with an activity score of 5 or more, or definite steatohepatitis (confirmed by two pathologists) with an activity score of 4. This secondary outcome measure is the number of participants who met this definition at baseline and did not meet this definition after 96 weeks of treatment and thus had a resolution of steatohepatitis. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 33 |
| Vitamin E | 29 |
| Placebo | 15 |
1 review available for choline and Cirrhosis
| Article | Year |
|---|---|
Stratifying Non-alcoholic Steatohepatitis With the Non-invasive Ultrasound Markers Shear Wave Dispersion Slope and Shear Wave Velocity: An Animal Study.
Topics: Animals; Biomarkers; Choline; Fibrosis; Liver; Liver Cirrhosis; Male; Methionine; Non-alcoholic Fatt | 2022 |
1 trial available for choline and Cirrhosis
| Article | Year |
|---|---|
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
Topics: Adolescent; Adult; Aged; Aging; Biopsy; Child; Choline; Choline Deficiency; Cohort Studies; Cross-Se | 2012 |
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
Topics: Adolescent; Adult; Aged; Aging; Biopsy; Child; Choline; Choline Deficiency; Cohort Studies; Cross-Se | 2012 |
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
Topics: Adolescent; Adult; Aged; Aging; Biopsy; Child; Choline; Choline Deficiency; Cohort Studies; Cross-Se | 2012 |
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
Topics: Adolescent; Adult; Aged; Aging; Biopsy; Child; Choline; Choline Deficiency; Cohort Studies; Cross-Se | 2012 |
32 other studies available for choline and Cirrhosis
| Article | Year |
|---|---|
Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis.
Topics: Animals; Carnitine O-Palmitoyltransferase; Choline; Fatty Acids; Fibrosis; Hepatic Stellate Cells; H | 2022 |
Ubiquitin-specific peptidase 10 ameliorates hepatic steatosis in nonalcoholic steatohepatitis model by restoring autophagic activity.
Topics: Animals; Autophagy; Choline; Fibrosis; Inflammation; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic | 2022 |
Astaxanthin Attenuates Nonalcoholic Steatohepatitis with Downregulation of Osteoprotegerin in Ovariectomized Mice Fed Choline-Deficient High-Fat Diet.
Topics: Animals; Choline; Diet; Diet, High-Fat; Down-Regulation; Estrogens; Female; Fibrosis; Humans; Liver; | 2023 |
Integrative Metabolomics and Proteomics Detected Hepatotoxicity in Mice Associated with Alkaloids from
Topics: Alkaloids; Animals; Chemical and Drug Induced Liver Injury; Choline; Eupatorium; Fibrosis; Glyceroph | 2022 |
Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.
Topics: Animals; Body Weight; Choline; Choline Deficiency; Diet; Fibrosis; Humans; Inflammation; Liver; Live | 2022 |
(Pro)Renin Receptor Antagonism Attenuates High-Fat-Diet-Induced Hepatic Steatosis.
Topics: Animals; Choline; Diet, High-Fat; Fibrosis; Lipids; Liver; Methionine; Mice; Mice, Inbred C57BL; Non | 2023 |
Theabrownin ameliorates liver inflammation, oxidative stress, and fibrosis in MCD diet-fed C57BL/6J mice.
Topics: Animals; Choline; Choline Deficiency; Diabetes Mellitus, Type 2; Diet; Fibrosis; Inflammation; Methi | 2023 |
Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
Topics: Amino Acids; Animals; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Choline; Choline D | 2023 |
Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Topics: Animals; Choline; Diet, High-Fat; Fatty Liver; Female; Fibrosis; Humans; Inflammation; Liver Cirrhos | 2023 |
Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease.
Topics: Animals; Bacteria; Bacterial Proteins; Choline; Disease Models, Animal; Enzyme Inhibitors; Fibrosis; | 2020 |
The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates.
Topics: Animals; Body Weight; Cell Line; Choline; Fibroblast Growth Factors; Fibrosis; Inflammation; Liver; | 2020 |
Nonlethal Inhibition of Gut Microbial Trimethylamine N-oxide Production Improves Cardiac Function and Remodeling in a Murine Model of Heart Failure.
Topics: Animals; Bacteria; Bacterial Proteins; Choline; Disease Models, Animal; Down-Regulation; Enzyme Inhi | 2020 |
High-Choline Diet Exacerbates Cardiac Dysfunction, Fibrosis, and Inflammation in a Mouse Model of Heart Failure With Preserved Ejection Fraction.
Topics: Animals; Choline; Diet; Fibrosis; Heart Failure; Humans; Inflammation; Mice; Mice, Inbred C57BL; Str | 2020 |
Feeding Diastolic Dysfunction: Is It a Bug?
Topics: Animals; Choline; Diet; Fibrosis; Heart Diseases; Heart Failure; Inflammation; Mice; Stroke Volume | 2020 |
MCD diet-induced steatohepatitis generates a diurnal rhythm of associated biomarkers and worsens liver injury in Klf10 deficient mice.
Topics: Animals; Apoptosis; Biomarkers; Caspase 3; Cells, Cultured; Choline; Circadian Rhythm; Diet; Disease | 2020 |
Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice.
Topics: Adenine; Albuminuria; Animals; Cardiomegaly; Choline; Disease Models, Animal; Female; Fibroblast Gro | 2021 |
The association between RGS4 and choline in cardiac fibrosis.
Topics: Animals; Choline; Fibroblasts; Fibrosis; Gene Silencing; Male; MAP Kinase Signaling System; Mice; My | 2021 |
Choline ameliorates cardiac hypertrophy by regulating metabolic remodelling and UPRmt through SIRT3-AMPK pathway.
Topics: AMP-Activated Protein Kinases; Animals; Cells, Cultured; Choline; Disease Models, Animal; Energy Met | 2019 |
Lycium barbarum polysaccharides improve hepatic injury through NFkappa-B and NLRP3/6 pathways in a methionine choline deficient diet steatohepatitis mouse model.
Topics: Animals; Antioxidants; Apoptosis; Choline; Diet; Disease Models, Animal; Drugs, Chinese Herbal; Fema | 2018 |
Intramedullary Reactive Fibrosis as Mimic of Prostate Cancer Bone Metastasis on 11C-Choline Positron Emission and Computed Tomography.
Topics: Bone and Bones; Bone Neoplasms; Carbon Radioisotopes; Choline; Fibrosis; Humans; Male; Middle Aged; | 2019 |
Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Case-Control Studies; Choline; Fasting; Fatty L | 2014 |
Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.
Topics: Amino Acids; Animals; Anti-Inflammatory Agents; Antioxidants; Binding Sites; Cell Line; Choline; Die | 2013 |
Protective role of autophagy in methionine-choline deficient diet-induced advanced nonalcoholic steatohepatitis in mice.
Topics: Animals; Autophagy; Choline; Diet; Endoplasmic Reticulum Stress; Fibrosis; Liver; Methionine; Mice; | 2016 |
Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure.
Topics: Animals; Bacteria; Cardiomegaly; Choline; Diet; Disease Models, Animal; Disease Progression; Fibrosi | 2016 |
TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice.
Topics: Animals; Chemokines; Choline; Diet; Down-Regulation; Fibrosis; Inflammation; Liver; Liver Cirrhosis; | 2016 |
Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice.
Topics: Animals; Biomarkers; Choline; Diet, High-Fat; Fibrosis; Gene Expression; Glucose Tolerance Test; Lip | 2016 |
Presence of bioactive lysophosphatidic acid in renal effluent of rats with unilateral ureteral obstruction.
Topics: Animals; Blotting, Western; Body Fluids; Choline; Chromatography, Liquid; Extracellular Space; Fibro | 2011 |
Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis.
Topics: Animals; Biomarkers; Choline; Choline Deficiency; Collagen Type I; Collagen Type III; Cyclooxygenase | 2012 |
Fatty cirrhosis in the rat. V. Regression upon return to normal diet.
Topics: Animals; Choline; Diet; Fatty Liver; Fibrosis; Liver Cirrhosis; Liver Cirrhosis, Experimental; Rats | 1963 |
Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats.
Topics: Animals; Carcinoma, Hepatocellular; Choline; Disease Models, Animal; Disease Progression; Fatty Live | 2006 |
Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappaB inhibition in a mouse model of chronic colitis.
Topics: Animals; Aziridines; CD4-Positive T-Lymphocytes; Choline; Chronic Disease; Colitis, Ulcerative; Croh | 2007 |
Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Amino Acids; Animal Nutritional Physiological Phenomena; Animals; Antic | 2002 |